Can semaglutide (the active ingredient in Ozempic) also slow down the ageing process?
There are early positive indications that semaglutide may be able to slow biological ageing processes, but the clinical evidence comes from one small study in HIV patients. Until trials in healthy older adults have been completed, it is too early to use semaglutide for this purpose outside its existing indications.
Semaglutide slowed biological ageing in one randomised trial involving 84 HIV patients who had developed body changes as a result of their treatment. After 32 weeks, participants were on average 2.2 to 4.9 years biologically younger on multiple epigenetic 'ageing clocks' (measurements of biological age based on DNA patterns), and the pace of ageing was 9% lower than in the placebo group. This is the most concrete clinical evidence available at present. However, it was a post-hoc analysis, not the pre-specified primary aim of the study, and the participants are not comparable to the average person.
How this might work mechanically has also been investigated. Semaglutide and related agents dampen chronic low-grade inflammation, improve mitochondrial function (the energy-generating structures inside cells) and stimulate autophagy, the process by which cells clear out their own waste. Cell-cleaning processes in models of Alzheimer's and Parkinson's disease also improved in cell and animal research, but this has not yet been confirmed in humans. Animal studies and laboratory findings are promising as pointers to the mechanism, but say nothing yet about whether this also leads to health gains in healthy older adults.
Specifically regarding vascular ageing, reviews describe that semaglutide and related agents may be able to reverse damage in blood vessels, but that evidence is mainly mechanistic and preclinical. An ongoing small study in 20 people aged 65 and older with overweight is now examining effects on muscle mass, walking ability and inflammatory markers, but results are not yet available.
What is missing is clear: there are no completed clinical trials in healthy older adults or in people without HIV, and the long-term safety of semaglutide as an 'anti-ageing agent' is unknown. Reviews emphasise that long-term side effects and individual variation are major unanswered questions. Until those answers are available, it is too early to recommend semaglutide as an anti-ageing treatment outside its approved indications.
The strongest evidence comes from one randomised trial in 84 HIV patients, as a post-hoc analysis: those are not the optimal conditions for a firm conclusion, and generalisation is limited. Beyond that, the answer rests on several review articles and cell and animal studies. The researchers behind those cell and animal studies themselves acknowledge that translation to humans has not yet been demonstrated. Dedicated clinical trials in healthy older adults are still in their infancy.
Can you remove microplastics from your blood vessels?
There is still too little research to answer this question.
Can you clear out "zombie cells" to slow down ageing?
The idea is biologically sound and produces impressive results in mice, but whether it works in humans and is safe remains unknown. Exercise and a healthy diet are, for now, the most concrete and safe ways to influence this ageing process.
How early in life should you start lowering your LDL cholesterol to prevent cardiovascular disease?
Starting as early as possible pays off: LDL damage accumulates from childhood, and every year that your LDL remains lower counts. If familial high cholesterol runs in your family, discuss with your doctor whether screening from a young age makes sense.
How reliable are the heart rate variability and readiness scores from your wearable actually for your health?
A good wearable measures resting heart rate reliably, but HRV scores and readiness are less accurate than they appear. Use them as a signal over the longer term, not as a hard daily diagnosis.